ENXTPA:SANPharmaceuticals
Sanofi Ends Riliprubart Trial As Neurology Pipeline Risks And Prospects Emerge
Sanofi (ENXTPA:SAN) has discontinued its Phase III MOBILIZE trial of riliprubart in chronic inflammatory demyelinating polyneuropathy after an interim analysis.
The decision followed data indicating the treatment was unlikely to reach sufficient efficacy targets, with no new safety concerns reported.
Sanofi plans to reassess its remaining riliprubart trials and related data to determine potential next steps for the program.
For investors watching ENXTPA:SAN, this move comes with the stock...